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Abstract
Although randomised controlled trials are the preferred basis for policy 
decisions on cancer screening, it remains difficult to assess all downstream 
effects of screening, particularly when screening options other than those 
in the specific trial design are being considered. Simulation models of the 
natural history of disease can play a role in quantifying harms and benefits of 
cancer screening scenarios. Recently, the US Preventive Services Task Force 
issued a C-recommendation on screening for prostate cancer for men aged 
55–69 years, implying at least moderate certainty that the benefit is small. 
However, modelling based on data from the European Randomized study 
of Screening for Prostate Cancer, which included quality-of-life estimates, 
showed that the ratio between benefits and harms is better, and likely to 
be reasonable, for men screened between the ages of 55 and 63 years 
(i.e. by using an earlier stopping age than applied in the trial setting). This 
commentary article considers the importance of simulation modelling in the 
decision-making process for (prostate) cancer screening. The paper also 
explores whether the recently published Cluster Randomized Trial of PSA 
Testing for Prostate Cancer, a trial of a single prostate specific antigen (PSA) 
testing intervention in the UK, changes the evidence for regular PSA testing 
for men aged 55–63 years by replicating the trial using a simulation model.  
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Key points
• The downstream effects of cancer
screening are difficult to assess from a
randomised controlled trial only, and it
is often impossible to compare several
screening strategies
• A well-calibrated and validated model can
help policy decision makers by ensuring
proper estimation of the harms and
benefits of cancer screening
• Modelling shows prostate specific antigen 
testing should preferably not be offered
after the age of 63, to ensure a reasonable 
balance between benefits and harms
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Introduction
Although randomised controlled trials (RCTs) are 
preferred as the basis for decisions regarding 
efficacy of cancer screening, it is almost impossible 
to directly assess long-term effects of screening such 
as overdiagnosis, overtreatment or life-years gained. 
This would, for instance, require a long or even lifelong 
follow-up of individuals in both the screening and control 
arms of such trials. Furthermore, finding the optimal 
screening strategy for a population would require formal 
comparisons of different screening strategies, which 
is impossible to do in a single RCT. This complexity of 
decision making has led to the need for (simulation) 
modelling of the natural history of disease. Modelling 
allows the impact of various screening strategies, as 
well as the long-term effects of cancer screening, to be 
assessed, provided that the model is well calibrated and 
validated. 
There are numerous examples of such quantifications 
being a valuable source for policy decision making. 
For example, the US Preventive Services Task Force 
(USPSTF)1-3 used results from modelling studies by 
Cancer Intervention and Surveillance Modeling Network 
(CISNET) groups on lung, breast and colorectal cancer 
screening4-6 to assess the optimum age at which 
to begin and end screening, the optimal screening 
interval, and the relative benefits and harms of different 
screening strategies. Similarly, the Dutch government has 
implemented a national program for colorectal cancer 
screening, for which the target age range, the type of 
test and the cut-off for referral were chosen based on 
modelling results from several pilot projects and predicted 
capacity needs for colonoscopy.7 The BreastScreen 
Australia Evaluation Advisory Committee (EAC), in its final 
report8, used evidence from modelling studies9,10 on the 
effectiveness of breast cancer screening by age. A more 
recent Australian example was modelling to assess the 
possible benefits and cost-effectiveness of the renewed 
national cervical cancer screening program in Australia.11
Prostate cancer screening
The risks and benefits of prostate specific antigen (PSA) 
testing for prostate cancer at a population level have 
been reviewed for decades, yet no country in the world 
has found sufficient evidence to fund an organised 
screening program. Reviews, including in Australia, 
have deemed that the harms outweigh the benefits at 
a population level, due primarily to the low specificity 
of the PSA test and the risks of unnecessary invasive 
treatments with significant side-effects.12 Prostate cancer 
is nonetheless a good example of how (simulation) 
modelling can help to answer important questions about 
improved targeting of early detection interventions, such 
as at what age a man might be encouraged to have his 
first PSA test and especially at what age a man who had 
already agreed to be tested might stop. 
Existing guidelines on prostate specific antigen 
screening are contradictory.13,14 For example, the USPSTF 
issued a C-recommendation on screening for prostate 
cancer for men aged 55–69 years, advising clinicians 
to inform men about the potential benefits (cancer 
deaths prevented, life-years gained and reduction of 
risk of advanced disease) and harms (overtreatment 
and living longer with the knowledge of a cancer 
diagnosis) of PSA screening.13 According to the USPSTF, 
a C-recommendation means there is at least moderate 
certainty that the benefit is small, and, therefore, 
selectively offering the test to individual patients based 
on professional judgement and patient preferences might 
be appropriate. Based on the 13-year follow-up of the 
European Randomized study of Screening for Prostate 
Cancer (ERSPC) trial, the USPSTF concluded that 
screening may prevent one to two prostate cancer deaths 
(over 13 years) per 1000 men screened, and 20–50% of 
men detected by screening may be overdiagnosed. The 
risk of overdiagnosis was calculated by comparing the 
number of cancers diagnosed in the screening group 
with the number diagnosed in the control group over 
follow-up years. However, estimating overdiagnosis over 
the given trial period only is often not enough, and, given 
the natural history of prostate cancer, longer follow-up is 
needed or has to be simulated.  
Pashayan et al.15 concluded that the benefit of 
prostate cancer screening in reducing advanced 
stage disease is counterbalanced by overdiagnosis, 
the latter being especially more frequent at older ages 
(65–69 years). Pinsky et al16 concluded that the burden 
from diagnosis of indolent disease (i.e. tumours that are 
unlikely to become symptomatic during a man’s lifetime) 
should be reduced by not diagnosing indolent disease at 
all and by not aggressively treating diagnosed indolent 
disease. One of the possible solutions for this could 
be stopping screening before the age of 69. A model 
which had been developed in the Australian context did 
not clearly indicate a favourable harm–benefit ratio for 
prostate cancer screening.17 A comprehensive Australian 
evaluation of the evidence also found no case for a 
PSA-based population screening program.18 There may, 
however, be a role for modelling to help inform targeted 
approaches, beyond the guidance available through 
conventional evidence review.
Predictions from a microsimulation 
analysis model (MISCAN)
A study using a microsimulation analysis (MISCAN) 
model, which was calibrated on ERSPC data and 
included quality-of-life estimates, showed that the ratio 
between benefits and harms is better for men screened 
at 55–63 years of age than for the broader age band 
(55–69/74) screened in the trial.19 The estimated effects 
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is now the largest RCT on PSA screening.21 However, in 
the CAP trial men were offered only one PSA test, and 
about 36% of them accepted that offer. Therefore, in 
practice, the number of PSA tests in the CAP trial is less 
than performed in the ERSPC trial (82 299 and 140 040, 
respectively). The result from the CAP trial must therefore 
be interpreted bearing in mind the low acceptance rate 
(36%) and single test applied only at age 50. 
We used a well-validated natural history model 
(MISCAN) to replicate the CAP trial, as best as we could, 
based on UK life tables, men screened by age, ERSPC 
incidence, treatment and survival rates, and assuming 
an 80% biopsy compliance and limited contamination 
rate of 2% per year. Analogous to experiences in the 
PLCO (Prostate, Lung, Colorectal and Ovarian Cancer 
Screening Trial)22, we assumed no difference in the 
natural history of prostate cancer, the performance of PSA 
testing and the benefit per screen in the UK compared 
with other countries in Europe or the US. Figure 1 shows 
our expected prostate cancer mortality curves for the 
screen and control arms of CAP. The small expected 
difference between the arms (given the one test at low 
compliance) is striking. We have estimated a prostate 
cancer mortality rate ratio of 0.94 after 10 years of follow-
up, not much different from the observed point estimate 
of 0.96, and well within the 95% confidence interval 
(0.85, 1.08). Extending the prostate cancer mortality 
prediction to 15 and 20 years of follow-up did not alter our 
estimate (0.94 and 0.95 mortality rate ratio, respectively). 
Therefore, our conclusion is that although the CAP trial of 
a single PSA testing intervention did not show statistically 
significant differences in prostate cancer mortality after 10 
years of follow-up, there may still be a potential mortality 
benefit demonstrated by microsimulation modelling. The 
low point estimate (4% statistically nonsignificant prostate 
cancer mortality reduction) observed in CAP cannot 
be interpreted to be inconsistent with the 27% benefit 
per screen as estimated from ERSPC, and confirmed 
in PLCO. This implies that, even when a trial shows no 
mortality benefit, well-validated modelling can strengthen 
the evidence on targeted interventions for improved early 
detection.
of screening men in different age groups are shown in 
Table 1. Model simulation is over the lifetime and thus the 
numbers of prostate cancer deaths averted (5–10 per 
1000 men) are larger than the prostate cancer mortality 
reduction found in the ERSPC trial at 13 years of follow-
up. Screening in the 55–63 years age group leads to a 
smaller number of prostate cancer deaths averted – 7 per 
1000 men, compared with 10 for the 55–69 years age 
group. However, the percentage loss in quality-adjusted 
life years (QALYs) – the difference between life years 
gained and QALYs gained divided by the life years 
gained – is smaller in the 55–63 years age group than in 
the 55–69 years age group; the number of overdiagnoses 
is also much lower (23 per 1000 men, compared 
with 49). Although the ratio between harms and benefits 
(overdiagnosis per prostate cancer death averted) is 
better for the initial core age group (55–69 years) than for 
the 64–69 years age group (who have the highest PSA 
test uptake in daily clinical practice), it is inferior to that for 
the 55–63 years age group (5.4 vs 3.2, respectively). This 
ratio of 3.2 between harms and benefits is almost similar 
to the ratio of 3 found by the UK independent breast 
screening panel.20 The UK panel concluded that this ratio 
is acceptable for breast cancer screening. 
Screening in the 55–63 years age group was found 
to have the best benefit and harm balance in this 
analysis.  In such circumstances there may be a case 
for the USPSTF to consider a B-recommendation for 
PSA testing for the 55–63 or 55–59 years age groups, 
as this modelling indicates there is moderate certainty 
that the net benefit is moderate to substantial. Further 
work, including research that improves understanding of 
the complexities of overdiagnosis in these specific age 
groups, would add to the quality of information necessary 
to confidently recommend such a change. 
One-time testing (CAP trial) versus 
regular PSA testing (ERSPC)
The Cluster Randomized Trial of PSA Testing for Prostate 
Cancer (CAP), conducted in the UK with 408 825 men, 
Table 1. Estimated effects of screening men at 2-year intervals compared with no screening
Screening 
age group 
(years)
PC deaths 
averteda
Overdiagnosed 
casesa
Overdiagnosed 
cases per PC 
death averted
Life years 
gaineda
Life years 
gained per 
PC death 
averted
QALYs 
gaineda
QALYs 
gained per 
PC death 
averted
% loss in 
QALYsb
55–63 7.0 23 3.2 62 9.0 51 7.3 17
64–69 5.0 35 7.0 39 7.8 22 4.4 43
55–69 9.8 49 5.4 83 8.4 61 6.7 27
PC = prostate cancer; QALYs = quality-adjusted life years
a Per 1000 men screened
b Percentage loss in QALYs calculated as the difference between life years gained and QALYs gained, divided by the life years gained. 
Note: The model simulates lifetime follow-up. A prostate specific antigen threshold of 3 ng/mL and an 80% attendance to the screening was 
assumed.
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